FDA Declines to Add Hepatitis Delta Virus to Tropical Disease List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
🇬🇧 English
The FDA declines to classify hepatitis delta virus infection as a tropical disease under the Federal Food, Drug, and Cosmetic Act. This means drug developers working on HDV treatments will not qualify for the tropical disease priority review voucher program on this basis. The agency reviewed whether HDV has no significant market in developed countries and whether it disproportionately affects poor and marginalized populations. It said it cannot conclude that the disease meets those legal criteria at this time.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA will not add hepatitis delta virus infection to the tropical disease list
- HDV drug developers will not receive tropical disease priority review voucher eligibility from this decision
- FDA leaves the docket process open for suggestions on other diseases
Affected Parties
pharmaceutical companies developing HDV treatmentsbiotech investors and business development teams+1 more…
Tags
FDA,hepatitis delta,priority review voucher…